Cupid Q1: Profit +194%, but 245x P/E valuation bubble looms

Cupid Limited's Q1 FY27 (Apr-Jun 2026) results vindicated the growth thesis but exposed extreme valuation risk. Net profit exploded 194% YoY to Rs 44.16 crore; operating income surged 159% YoY. Management raised FY27 revenue guidance to Rs 725-750 crore and reiterated Rs 1,500 crore target by FY29, implying 50% annualized growth. The business is firing on all cylinders. Yet the stock's 6,776% three-year rally has priced in all of this and more. At Rs 265 (Sep 18), Cupid trades at 245x trailing P/E, a valuation that admits no errors and leaves zero margin for missed guidance or slowdown. Q4 FY26 already flagged that profit growth "masks valuation concerns." The risk is binary: either the company executes perfectly for five years (unlikely given execution risk in scaling condom manufacturing and exports), or the stock corrects sharply when growth inevitably slows or guidance misses. Retail FOMO has driven marginal pricing; institutional sell signals could accelerate a violent drawdown. Macro tailwinds—rising awareness, contraceptive penetration in tier-2/3 towns, export momentum—remain intact. But the valuation is the binding constraint. Cupid's own quarterly profit of Rs 44.16 crore annualizes to ~Rs 176.6 crore PAT on FY27 guided revenue of Rs 737.5 crore midpoint, implying 24% net margin and 1,500 crore market cap by FY29 (if guidance holds). At current price of Rs 265 and ~40 crore shares, market cap is Rs 10,600 crore; that implies Rs 7.5x FY29 PB on pro forma ROE, an extreme multiple even for high-growth stories. Entry requires a 60% correction; hold above Rs 180, exit above Rs 300. Entry: Below Rs 200 accumulation, tactical hold above Rs 180 retest. Invalidation if guidance upgraded to Rs 800+ for FY27 and profit margin expands above 26%. DISCLOSURE This post is for informational and educational purposes. I do not hold [] at the time of writing. Please do your own research and consult a financial advisor before trading or investing.